Zacks.com on MSN1h
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue EstimatesNektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago. These figures ...
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...
Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: ...
(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...
Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand Capital Partners for $90 million. Ascendis Pharma and Novo ...
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback